![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SPINT2 |
Gene summary for SPINT2 |
![]() |
Gene information | Species | Human | Gene symbol | SPINT2 | Gene ID | 10653 |
Gene name | serine peptidase inhibitor, Kunitz type 2 | |
Gene Alias | DIAR3 | |
Cytomap | 19q13.2 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A0A140VJV6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10653 | SPINT2 | GSM4909280 | Human | Breast | Precancer | 3.84e-03 | -6.73e-01 | 0.0305 |
10653 | SPINT2 | GSM4909281 | Human | Breast | IDC | 2.26e-09 | 3.08e-01 | 0.21 |
10653 | SPINT2 | GSM4909282 | Human | Breast | IDC | 2.28e-12 | 3.11e-01 | -0.0288 |
10653 | SPINT2 | GSM4909285 | Human | Breast | IDC | 4.84e-44 | 5.52e-01 | 0.21 |
10653 | SPINT2 | GSM4909286 | Human | Breast | IDC | 5.38e-08 | -1.41e-01 | 0.1081 |
10653 | SPINT2 | GSM4909291 | Human | Breast | IDC | 5.32e-14 | 4.24e-01 | 0.1753 |
10653 | SPINT2 | GSM4909293 | Human | Breast | IDC | 1.81e-04 | 2.62e-01 | 0.1581 |
10653 | SPINT2 | GSM4909294 | Human | Breast | IDC | 1.52e-14 | -2.81e-01 | 0.2022 |
10653 | SPINT2 | GSM4909296 | Human | Breast | IDC | 6.23e-07 | -1.80e-01 | 0.1524 |
10653 | SPINT2 | GSM4909297 | Human | Breast | IDC | 4.98e-16 | -1.57e-01 | 0.1517 |
10653 | SPINT2 | GSM4909298 | Human | Breast | IDC | 6.17e-06 | 2.40e-01 | 0.1551 |
10653 | SPINT2 | GSM4909305 | Human | Breast | IDC | 9.67e-03 | 2.45e-01 | 0.0436 |
10653 | SPINT2 | GSM4909306 | Human | Breast | IDC | 8.91e-56 | 6.21e-01 | 0.1564 |
10653 | SPINT2 | GSM4909307 | Human | Breast | IDC | 1.27e-03 | 2.30e-01 | 0.1569 |
10653 | SPINT2 | GSM4909309 | Human | Breast | IDC | 1.28e-02 | 1.45e-02 | 0.0483 |
10653 | SPINT2 | GSM4909311 | Human | Breast | IDC | 3.22e-37 | -1.93e-01 | 0.1534 |
10653 | SPINT2 | GSM4909312 | Human | Breast | IDC | 1.27e-10 | 1.88e-01 | 0.1552 |
10653 | SPINT2 | GSM4909313 | Human | Breast | IDC | 1.56e-02 | 1.34e-01 | 0.0391 |
10653 | SPINT2 | GSM4909315 | Human | Breast | IDC | 1.66e-09 | 3.63e-02 | 0.21 |
10653 | SPINT2 | GSM4909316 | Human | Breast | IDC | 1.62e-05 | -1.02e-01 | 0.21 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:006071112 | Prostate | Tumor | labyrinthine layer development | 17/3246 | 44/18723 | 6.56e-04 | 4.66e-03 | 17 |
GO:001402012 | Prostate | Tumor | primary neural tube formation | 29/3246 | 94/18723 | 9.27e-04 | 6.10e-03 | 29 |
GO:007171111 | Prostate | Tumor | basement membrane organization | 13/3246 | 31/18723 | 1.14e-03 | 7.27e-03 | 13 |
GO:000184312 | Prostate | Tumor | neural tube closure | 27/3246 | 88/18723 | 1.50e-03 | 9.25e-03 | 27 |
GO:006060612 | Prostate | Tumor | tube closure | 27/3246 | 89/18723 | 1.80e-03 | 1.06e-02 | 27 |
GO:002191512 | Prostate | Tumor | neural tube development | 41/3246 | 152/18723 | 1.91e-03 | 1.12e-02 | 41 |
GO:00485685 | Prostate | Tumor | embryonic organ development | 93/3246 | 427/18723 | 9.84e-03 | 4.18e-02 | 93 |
GO:000716326 | Skin | AK | establishment or maintenance of cell polarity | 53/1910 | 218/18723 | 1.32e-09 | 1.26e-07 | 53 |
GO:000170120 | Skin | AK | in utero embryonic development | 75/1910 | 367/18723 | 3.09e-09 | 2.62e-07 | 75 |
GO:005254727 | Skin | AK | regulation of peptidase activity | 88/1910 | 461/18723 | 4.65e-09 | 3.44e-07 | 88 |
GO:004586127 | Skin | AK | negative regulation of proteolysis | 72/1910 | 351/18723 | 5.40e-09 | 3.90e-07 | 72 |
GO:000206425 | Skin | AK | epithelial cell development | 51/1910 | 220/18723 | 1.50e-08 | 9.13e-07 | 51 |
GO:005254827 | Skin | AK | regulation of endopeptidase activity | 82/1910 | 432/18723 | 2.03e-08 | 1.18e-06 | 82 |
GO:004860819 | Skin | AK | reproductive structure development | 77/1910 | 424/18723 | 3.56e-07 | 1.36e-05 | 77 |
GO:006145820 | Skin | AK | reproductive system development | 77/1910 | 427/18723 | 4.76e-07 | 1.74e-05 | 77 |
GO:002240725 | Skin | AK | regulation of cell-cell adhesion | 79/1910 | 448/18723 | 8.55e-07 | 2.81e-05 | 79 |
GO:001046625 | Skin | AK | negative regulation of peptidase activity | 51/1910 | 262/18723 | 4.43e-06 | 1.07e-04 | 51 |
GO:005134626 | Skin | AK | negative regulation of hydrolase activity | 67/1910 | 379/18723 | 5.22e-06 | 1.21e-04 | 67 |
GO:000189020 | Skin | AK | placenta development | 33/1910 | 144/18723 | 6.49e-06 | 1.47e-04 | 33 |
GO:001095120 | Skin | AK | negative regulation of endopeptidase activity | 49/1910 | 252/18723 | 6.98e-06 | 1.55e-04 | 49 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SPINT2 | SNV | Missense_Mutation | novel | c.367T>A | p.Ser123Thr | p.S123T | O43291 | protein_coding | tolerated(0.1) | benign(0.003) | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
SPINT2 | SNV | Missense_Mutation | c.68N>G | p.Ser23Cys | p.S23C | O43291 | protein_coding | tolerated_low_confidence(0.06) | benign(0) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
SPINT2 | SNV | Missense_Mutation | rs11548458 | c.142N>T | p.Arg48Trp | p.R48W | O43291 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SPINT2 | SNV | Missense_Mutation | c.443N>A | p.Arg148His | p.R148H | O43291 | protein_coding | deleterious(0) | possibly_damaging(0.709) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
SPINT2 | SNV | Missense_Mutation | c.510N>T | p.Lys170Asn | p.K170N | O43291 | protein_coding | deleterious(0) | possibly_damaging(0.74) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
SPINT2 | deletion | Frame_Shift_Del | c.205delN | p.Gly70AlafsTer10 | p.G70Afs*10 | O43291 | protein_coding | TCGA-CM-4743-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | capecitabine | SD | |||
SPINT2 | SNV | Missense_Mutation | rs746801741 | c.457G>A | p.Val153Met | p.V153M | O43291 | protein_coding | deleterious(0.05) | possibly_damaging(0.75) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SPINT2 | SNV | Missense_Mutation | novel | c.16N>A | p.Gly6Arg | p.G6R | O43291 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.652) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SPINT2 | SNV | Missense_Mutation | c.316N>T | p.Ala106Ser | p.A106S | O43291 | protein_coding | tolerated(0.06) | benign(0.074) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SPINT2 | SNV | Missense_Mutation | c.580N>T | p.Leu194Phe | p.L194F | O43291 | protein_coding | tolerated(0.7) | benign(0.04) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |